Please use this identifier to cite or link to this item:
|Title:||Is a standard fixed dose of mycophenolate mofetil ideal for all patients?||Authors:||Yau, W.-P.
|Issue Date:||Dec-2007||Citation:||Yau, W.-P., Vathsala, A., Lou, H.-X., Chan, E. (2007-12). Is a standard fixed dose of mycophenolate mofetil ideal for all patients?. Nephrology Dialysis Transplantation 22 (12) : 3638-3645. ScholarBank@NUS Repository. https://doi.org/10.1093/ndt/gfm468||Abstract:||Background. A standard fixed dose of 2 g/day of mycophenolate mofetil (MMF), irrespective of total body weight (TBW), is recommended when used in combination with cyclosporine and corticosteroids in renal transplantation. Methods. To determine the optimal MMF dose in a population with wide variation in TBW, steady-state pharmacokinetics of mycophenolic acid (MPA) was performed in 53 Asian (Chinese, Malay, Indian, Eurasian) renal transplant recipients (RTX) receiving MMF [250-1000 mg twice daily (BD)] for at least 3 months. Blood samples were collected at 0, 0.5, 1, 1.5, 2 and 6 h after the MMF dose and total MPA quantified using HPLC. Results. Drug exposure, as evaluated by AUC ss, 0-12, demonstrated a significant positive correlation with TBW-adjusted MMF dose (outliers omitted: r2 = 0.49, P < 0.0005). An AUCss, 0-12 of 45 mg h/l could be attained with an MMF dose of 12 mg/kg BD. Conclusion. This study proposes that MMF should be dosed based on TBW rather than a fixed dose regimen in RTX. © The Author . Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.||Source Title:||Nephrology Dialysis Transplantation||URI:||http://scholarbank.nus.edu.sg/handle/10635/106092||ISSN:||09310509||DOI:||10.1093/ndt/gfm468|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 17, 2020
WEB OF SCIENCETM
checked on Jan 9, 2020
checked on Jan 18, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.